| Literature DB >> 27681714 |
Adnan Amin1, Emmy Tuenter2, Paul Cos3, Louis Maes4, Vassiliki Exarchou5, Sandra Apers6, Luc Pieters7.
Abstract
The exudate of Ferula narthex Boiss. (Apiaceae) is widely used in the Indian subcontinent as a spice and because of its health effects. Six sesquiterpene coumarins have been isolated from this exudate: feselol, ligupersin A, asacoumarin A, 8'-O-acetyl-asacoumarin A, 10'R-karatavacinol and 10'R-acetyl-karatavacinol. Based on its use in infectious and diabetic conditions, the isolated constituents were evaluated for antimicrobial and antiglycation activities. Some compounds showed activity against protozoal parasites, asacoumarin A being the most active one against Plasmodium falciparum K1 (IC50 1.3 μM). With regard to antiglycation activity, in the BSA-glucose test, ligupersin A displayed the highest activity (IC50 0.41 mM), being more active than the positive control aminiguanidine (IC50 1.75 mM). In the BSA-MGO assay, the highest activity was shown by 8'-O-acetyl-asacoumarin A (IC50 1.03 mM), being less active than aminoguanidine (IC50 0.15 mM). Hence, the antiglycation activity of the isolated constituents was due to both oxidative and non-oxidative modes of inhibition.Entities:
Keywords: Apiaceae; Ferula narthex; antiglycation activity; antiprotozoal activity; exudate; sesquiterpene coumarins
Year: 2016 PMID: 27681714 PMCID: PMC6274357 DOI: 10.3390/molecules21101287
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of isolated constituents (1–6).
Antibacterial, antifungal and cytotoxic activities of Ferula narthex fractions.
| Sample | IC50 μg/mL | ||||
|---|---|---|---|---|---|
| MRC-5 | |||||
| MeOH 90% | 19.9 | >64 | >64 | 22.0 | 36.5 |
| Chloroform | >64 | >64 | >64 | >64 | 49.8 |
| Ethyl acetate | >64 | >64 | >64 | >64 | >64 |
| >64 | >64 | >64 | >64 | ||
| >64 | >64 | >64 | >64 | >64 | |
| Aqueous | >64 | >64 | >64 | >64 | >64 |
MRC-5: Human fetal lung fibroblasts; S. aureus: Staphylococcus aureus; E. coli: Escherichia coli; C. albicans: Candida albicans. Reference compounds: Tamoxifen (MRC-5) IC50 11.4 μg/mL; erythromycin (S. aureus) IC50 11.2 μg/mL; trimethoprim (E. coli) IC50 0.25 μg/mL; miconazole (C. albicans) IC50 5.99 μg/mL; terbinafine (M. canis) IC50 0.11 μg/mL.
Antiprotozoal and cytotoxic activities of isolated compounds from Ferula narthex (IC50, μM).
| Compound No. | IC50 (μM) | |||||
|---|---|---|---|---|---|---|
| MRC5 | Pf-K1 | PMM | ||||
| 8.0 | 22.4 | 8.1 | 8.6 | 6.8 | 8 | |
| 31.7 | 7.4 | 32.4 | 19.1 | 12.7 | 32 | |
| 11.7 | 1.3 | 32.6 | 10.5 | 12.7 | 32 | |
| 20.4 | 16.0 | 32.4 | 9.4 | 32.4 | 32 | |
MRC-5: Human fetal lung fibroblasts; Pf-K1: Plasmodium falciparum K1; T. bruc.: Trypanosoma brucei; T. cruz.: Trypanosoma cruzi; L .inf.: Leishmania infantum; PMM: Peritoneal Murine Macrophages. Reference compounds: Tamoxifen (MRC-5), IC50 11.3 μM; suramine (T. brucei), IC50 0.03 μM; fungizone (L. inf.), IC50 1.1 μM; chloroquine (Pf-K1), IC50 0.16 μM; benznidazole (T. cruzi), IC50 3.3 μM; erythromycin (S. aureus), IC50 11.3 μM; chloramphenicol (E. coli), IC50 4.9 μM; miconazole (C. albicans), IC50 10.5 μM; terbinafine (A. fumigatus), IC50 0.8 μM.
Antiglycation (AGEs) activity of compounds 1–6.
| Compound No. | BSA-Glucose BSA-MGO | |||
|---|---|---|---|---|
| % Inhibition a | IC50 (mM) | % Inhibition b | IC50 (mM) | |
| 47 | - | 1.71 | ||
| 0.41 | 40 | - | ||
| 44 | - | 1.03 | ||
| 1.83 | 35 | - | ||
| 32 | - | - | 1.86 | |
| 36 | - | 20 | - | |
| Aminoguanidine | 1.75 | 0.15 | ||
| Quercetin | 0.23 | 0.35 | ||
a at 0.25 mM; b at 2 mM.